Literature DB >> 33388855

Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect.

Yu-Fan Chuang1,2, Andrew J Phipps3, Fan-Li Lin1,2, Valerie Hecht4, Alex W Hewitt2,5,6, Peng-Yuan Wang7,8, Guei-Sheung Liu9,10,11.   

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system provides a groundbreaking genetic technology that allows scientists to modify genes by targeting specific genomic sites. Due to the relative simplicity and versatility of the CRISPR/Cas system, it has been extensively applied in human genetic research as well as in agricultural applications, such as improving crops. Since the gene editing activity of the CRISPR/Cas system largely depends on the efficiency of introducing the system into cells or tissues, an efficient and specific delivery system is critical for applying CRISPR/Cas technology. However, there are still some hurdles remaining for the translatability of CRISPR/Cas system. In this review, we summarized the approaches used for the delivery of the CRISPR/Cas system in mammals, plants, and aquacultures. We further discussed the aspects of delivery that can be improved to elevate the potential for CRISPR/Cas translatability.

Entities:  

Keywords:  CRISPR/Cas; Gene delivery; Gene editing; Gene therapy

Mesh:

Year:  2021        PMID: 33388855     DOI: 10.1007/s00018-020-03725-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  251 in total

1.  Dynamics of CRISPR-Cas9 genome interrogation in living cells.

Authors:  Spencer C Knight; Liangqi Xie; Wulan Deng; Benjamin Guglielmi; Lea B Witkowsky; Lana Bosanac; Elisa T Zhang; Mohamed El Beheiry; Jean-Baptiste Masson; Maxime Dahan; Zhe Liu; Jennifer A Doudna; Robert Tjian
Journal:  Science       Date:  2015-11-13       Impact factor: 47.728

Review 2.  Nuclear delivery of macromolecules: barriers and carriers.

Authors:  Mattias Belting; Staffan Sandgren; Anders Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2004-12-28       Impact factor: 15.470

3.  Structural basis for CRISPR RNA-guided DNA recognition by Cascade.

Authors:  Matthijs M Jore; Magnus Lundgren; Esther van Duijn; Jelle B Bultema; Edze R Westra; Sakharam P Waghmare; Blake Wiedenheft; Umit Pul; Reinhild Wurm; Rolf Wagner; Marieke R Beijer; Arjan Barendregt; Kaihong Zhou; Ambrosius P L Snijders; Mark J Dickman; Jennifer A Doudna; Egbert J Boekema; Albert J R Heck; John van der Oost; Stan J J Brouns
Journal:  Nat Struct Mol Biol       Date:  2011-04-03       Impact factor: 15.369

Review 4.  Therapeutic genome editing: prospects and challenges.

Authors:  David Benjamin Turitz Cox; Randall Jeffrey Platt; Feng Zhang
Journal:  Nat Med       Date:  2015-02       Impact factor: 53.440

5.  A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Authors:  Martin Jinek; Krzysztof Chylinski; Ines Fonfara; Michael Hauer; Jennifer A Doudna; Emmanuelle Charpentier
Journal:  Science       Date:  2012-06-28       Impact factor: 47.728

Review 6.  CRISPR-Cas systems for editing, regulating and targeting genomes.

Authors:  Jeffry D Sander; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-03-02       Impact factor: 54.908

Review 7.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

Authors:  Thomas Gaj; Charles A Gersbach; Carlos F Barbas
Journal:  Trends Biotechnol       Date:  2013-05-09       Impact factor: 19.536

8.  CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.

Authors:  Elitza Deltcheva; Krzysztof Chylinski; Cynthia M Sharma; Karine Gonzales; Yanjie Chao; Zaid A Pirzada; Maria R Eckert; Jörg Vogel; Emmanuelle Charpentier
Journal:  Nature       Date:  2011-03-31       Impact factor: 49.962

9.  The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.

Authors:  Krzysztof Chylinski; Anaïs Le Rhun; Emmanuelle Charpentier
Journal:  RNA Biol       Date:  2013-04-05       Impact factor: 4.652

Review 10.  CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future.

Authors:  Fathema Uddin; Charles M Rudin; Triparna Sen
Journal:  Front Oncol       Date:  2020-08-07       Impact factor: 6.244

View more
  9 in total

Review 1.  Engineering Closed-Loop, Autoregulatory Gene Circuits for Osteoarthritis Cell-Based Therapies.

Authors:  Rhima M Coleman
Journal:  Curr Rheumatol Rep       Date:  2022-04-11       Impact factor: 4.592

Review 2.  CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.

Authors:  Cedric Happi Mbakam; Gabriel Lamothe; Guillaume Tremblay; Jacques P Tremblay
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

Review 3.  Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.

Authors:  Alesya G Bykonya; Alexander V Lavrov; Svetlana A Smirnikhina
Journal:  Mol Biotechnol       Date:  2022-03-24       Impact factor: 2.695

4.  Emerging therapeutics.

Authors:  Gennaro Ciliberto
Journal:  J Transl Med       Date:  2021-05-05       Impact factor: 5.531

Review 5.  Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases.

Authors:  Ankit Kumar Dubey; Vijai Kumar Gupta; Małgorzata Kujawska; Gorka Orive; Nam-Young Kim; Chen-Zhong Li; Yogendra Kumar Mishra; Ajeet Kaushik
Journal:  J Nanostructure Chem       Date:  2022-02-14

Review 6.  Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment.

Authors:  Elena Codrici; Ionela-Daniela Popescu; Cristiana Tanase; Ana-Maria Enciu
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

Review 7.  CRISPR/Cas systems usher in a new era of disease treatment and diagnosis.

Authors:  Ruiting Li; Qin Wang; Kaiqin She; Fang Lu; Yang Yang
Journal:  Mol Biomed       Date:  2022-10-14

Review 8.  Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases.

Authors:  Yashashree Karpe; Zhenyu Chen; Xue-Jun Li
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-12

Review 9.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.